3.755
Larimar Therapeutics Inc Borsa (LRMR) Ultime notizie
What analysts say about Larimar Therapeutics Inc. stockDynamic growth stocks - Autocar Professional
What drives Larimar Therapeutics Inc. stock priceRapidly expanding wealth - jammulinksnews.com
Is Larimar Therapeutics Inc. a good long term investmentOutstanding risk-reward balance - jammulinksnews.com
Larimar Therapeutics Inc. Stock Analysis and ForecastMarket-beating returns - jammulinksnews.com
Larimar Therapeutics Reports Q1 2025 Results and Advances Nomlabofusp Development - MSN
Is Larimar Therapeutics Inc. stock overhyped or has real potentialHigh Return Investment Tips - Newser
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - Yahoo Finance
5 Small Drug Stocks To Buy Amid Trump's New Tariff Threats - Barchart.com
Why Larimar Therapeutics Inc. stock attracts strong analyst attentionTop Analyst Picks - Newser
What makes Larimar Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data - MSN
Larimar Nears Data Readout For Nomlabofusp In Rare Inherited Disorder - RTTNews
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia - MarketScreener
Larimar Therapeutics Publishes Nonclinical Data Supporting the Therapeutic Potential of Nomlabofusp in Patients with Friedreich's Ataxia | LRMR Stock News - GuruFocus
Larimar Therapeutics Publishes Nonclinical Findings Supporting Nomlabofusp's Accelerated Approval Pathway for Friedreich’s Ataxia Treatment - Nasdaq
Larimar Therapeutics Publishes Nonclinical Data Supporting - GlobeNewswire
First Disease-Modifying Treatment for Friedreich's Ataxia Advances Toward FDA Accelerated Approval - Stock Titan
Larimar Therapeutics, Inc.(NasdaqGM: LRMR) added to Russell 3000 Value Index - MarketScreener
Larimar Therapeutics Aligns with FDA Guidance, Revises Nomlabofusp Submission Timeline - MSN
Guggenheim Reiterates Buy Rating for Larimar Therapeutics (LRMR) - GuruFocus
Larimar Therapeutics’ (LRMR) Buy Rating Reaffirmed at Guggenheim - Defense World
Analyst Lowers Price Target for Larimar Therapeutics (LRMR) | LRMR Stock News - GuruFocus
Larimar Therapeutics (LRMR) Target Price Reduced by Wedbush Amid FDA Delay | LRMR Stock News - GuruFocus
Larimar Therapeutics (LRMR) Sees Buying Opportunity After Share Decline | LRMR Stock News - GuruFocus
Larimar Therapeutics Announces FDA Recommendations on Safety Database, and Other Details of Nomlabofusp BLA Submission for Friedreich's Ataxia Program | LRMR Stock News - GuruFocus
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia - The Manila Times
Larimar Therapeutics Announces Regulatory Update Call on - GlobeNewswire
Millennium Management LLC Acquires Additional Shares in Larimar Therapeutics Inc - GuruFocus
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):